Ardigen’s AI and computational biology capabilities will strengthen VERAXA’s in-house AI efforts to optimize cancer target pair selection for conditionally active T cell engagers and antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results